Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hemoglobin crosfumaril

Drug Profile

Hemoglobin crosfumaril

Alternative Names: DCLHb; Diaspirin crosslinked haemoglobin; Haemoglobin crosfumaril; HemAssist; Human haemoglobin - Baxter

Latest Information Update: 10 Jul 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter Healthcare Corporation
  • Class
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Septic shock
  • Discontinued Hypovolaemia; Shock; Stroke; Vascular disorders

Most Recent Events

  • 20 Apr 2000 Preclinical development for Septic shock in Canada (IV-infusion)
  • 29 Jun 1999 Discontinued-Clinical for Stroke in USA (IV)
  • 29 Jun 1999 A study has been added to the adverse events and Neurological disorders therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top